A Phase 1 Dose Escalation Study of IPI-493

This study has been terminated.
(Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on retaspimycin)
Sponsor:
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00724425
First received: July 25, 2008
Last updated: April 14, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)